<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01970579</url>
  </required_header>
  <id_info>
    <org_study_id>AAG-G-H-1214</org_study_id>
    <nct_id>NCT01970579</nct_id>
  </id_info>
  <brief_title>Clinical Trial on Peripheral Arteries Treated With SeQuent® Please P Paclitaxel Coated Balloon Catheter</brief_title>
  <acronym>ConSeQuent</acronym>
  <official_title>Clinical Trial on Peripheral Arteries Treated With SeQuent® Please P Paclitaxel Coated Balloon Catheter</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>B. Braun Melsungen AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>B. Braun Melsungen AG</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to assess the safety and efficacy of the paclitaxelreleasing balloon&#xD;
      catheter SeQuent® Please P to treat de novo and restenotic lesions in the superficial femoral&#xD;
      artery and the proximal two segments of the popliteal artery with reference diameters ≥ 4mm &amp;&#xD;
      ≤ 7mm and lesion lengths ≥ 4 cm &amp; ≤ 27 cm. It is the intention of this trial to treat&#xD;
      suitable target lesions with DCB only.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">December 2019</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Late Lumen Loss</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">153</enrollment>
  <condition>Stenosis</condition>
  <condition>Restenosis</condition>
  <arm_group>
    <arm_group_label>Paclitaxel coated balloon</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>uncoated PTA catheter</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Paclitaxel coated balloon</intervention_name>
    <description>Treatment of target lesion with study balloon (coated). Diameter of treatment balloon = RVD&#xD;
Each study balloon must only be used once (except postdilatation is necessary which may be done with the same balloon used for the initial dilatation)&#xD;
Treatment balloon must be 20 mm longer than lesion length (to assure balloon overlap of 10 mm proximal and distal to lesion)&#xD;
If two treatment balloons are necessary overlap between the balloon must be 10 mm&#xD;
Inflation pressure 7-10 atm&#xD;
Intraluminal defects or haziness should be treated with additional inflations and/or aggressive anti-platelet agents or bailout stenting</description>
    <arm_group_label>Paclitaxel coated balloon</arm_group_label>
    <other_name>SeQuent® Please P</other_name>
    <other_name>Drug coated balloon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>uncoated PTA catheter</intervention_name>
    <description>Treatment of target lesion with study balloon (uncoated). Diameter of treatment balloon = RVD&#xD;
Each study balloon must only be used once (except postdilatation is necessary which may be done with the same balloon used for the initial dilatation)&#xD;
Treatment balloon must be 20 mm longer than lesion length (to assure balloon overlap of 10 mm proximal and distal to lesion)&#xD;
If two treatment balloons are necessary overlap between the balloon must be 10 mm&#xD;
Inflation pressure 7-10 atm&#xD;
Intraluminal defects or haziness should be treated with additional inflations and/or aggressive anti-platelet agents or bailout stenting.</description>
    <arm_group_label>uncoated PTA catheter</arm_group_label>
    <other_name>POBA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Willingness to treat the target lesion according to the DCB only concept&#xD;
&#xD;
          -  Patients in Rutherford classes 2 through 4 (corresponding to Fontaine stage IIb to&#xD;
             III)&#xD;
&#xD;
          -  Patients eligible for peripheral revascularization by means of PTA&#xD;
&#xD;
          -  Patients must be ≥ 18 years of age&#xD;
&#xD;
          -  Patients who are mentally and linguistically able to understand the aim of the study&#xD;
             and to show sufficient compliance in following the study protocol&#xD;
&#xD;
          -  Patients must agree to undergo the 6-month angiographic and clinical follow-up&#xD;
&#xD;
          -  Patients must agree to undergo the 1 and 2 year clinical follow-up&#xD;
&#xD;
          -  Patient is able to verbally acknowledge an understanding of the associated risks,&#xD;
             benefits, and treatment alternatives to therapeutic options of this trial. The&#xD;
             patients, by providing their informed consent, agree to these risks and benefits as&#xD;
             stated in the patient informed consent document.&#xD;
&#xD;
          -  Peripheral lesions in the native SFA or popliteal artery with reference vessel&#xD;
             diameters between ≥ 4.0 and ≤ 7.0 mm, lesions lengths ≥ 4 cm and ≤ 27 cm as&#xD;
             angiographically documented&#xD;
&#xD;
          -  Diameter stenosis pre-procedure must be ≥ 70%&#xD;
&#xD;
          -  Target lesion in the SFA or popliteal artery (first two proximal segments)*.&#xD;
&#xD;
             * as far as applicable distance of the target lesion to a previously implanted stent&#xD;
             should be about 1cm&#xD;
&#xD;
          -  Vessels must have adequate runoff with at least one vessel to the foot.&#xD;
&#xD;
          -  Treatment of max. two lesions is permitted.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with Rutherford class 5 or 6&#xD;
&#xD;
          -  Women who are known or suspected to be pregnant. Hence, patients will be advised to&#xD;
             use an adequate birth control method up to and including the 6-month follow-up.&#xD;
&#xD;
          -  Patients with an expected life span of less than 24 months&#xD;
&#xD;
          -  Patients with bleeding diathesis in whom anticoagulation or anti-platelet medication&#xD;
             is contraindicated&#xD;
&#xD;
          -  Patients who had a cerebral stroke &lt; 6 months prior to the procedure&#xD;
&#xD;
          -  Patients with unstable angina pectoris&#xD;
&#xD;
          -  Patients with acute myocardial infarction within the past 2 weeks&#xD;
&#xD;
          -  Patient participates in other clinical trials involving any investigational device or&#xD;
             drug that interfere with the effects to be studied in this trial.&#xD;
&#xD;
          -  Interventional treatment at the contralateral leg within 2 weeks prior to or after the&#xD;
             study intervention&#xD;
&#xD;
          -  Untreated hyperthyroidism&#xD;
&#xD;
          -  Patient has presence or history of severe renal failure (GFR &lt; 30ml/min) and is&#xD;
             therefore not eligible for angiography.&#xD;
&#xD;
          -  Post transplantation of any organ or immune suppressive medication&#xD;
&#xD;
          -  Other disease to jeopardize follow-up (e.g. malignoma)&#xD;
&#xD;
          -  Addiction to any drug or to alcohol (WHO definition)&#xD;
&#xD;
          -  Patients with clinically significant aneurysmal disease of the popliteal, femoral or&#xD;
             iliac artery and patients with history of clinically significant abdominal aortic&#xD;
             aneurysm&#xD;
&#xD;
          -  Patients with any type of surgical/interventional procedures within 4 weeks prior to&#xD;
             or planned after study intervention (if those may interfere with the peripheral study&#xD;
             intervention and/or patient's ability to perform the follow up examinations)&#xD;
&#xD;
          -  Conditions which prevent the intake of the double anti-platelet therapy for two months&#xD;
&#xD;
          -  Patients with contraindication for drug-eluting balloon angioplasty given in the&#xD;
             instruction for use&#xD;
&#xD;
          -  Patients under administrative or judicial custody (§20 Act on Medical Devices,&#xD;
             Germany)&#xD;
&#xD;
          -  Strongly calcified lesions with circumferential presence of calcifications and a&#xD;
             lesion length of &gt; 4 cm&#xD;
&#xD;
          -  Chronic total occlusions longer than 10 cm&#xD;
&#xD;
          -  Lesion below the knee requiring treatment&#xD;
&#xD;
          -  Target lesion within a bypass graft&#xD;
&#xD;
          -  In-stent restenosis&#xD;
&#xD;
          -  Lesions treated with DCB&#xD;
&#xD;
          -  Concomitant use of atherectomy, cryoplasty or laser therapy&#xD;
&#xD;
          -  Inflow lesion (proximal to the study lesion) with flow limitation not being&#xD;
             successfully treated prior to the study lesion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Albrecht, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vivantes Klinikum Neukölln, Berlin, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitäts-Herzzentrum Freiburg Bad Krozingen</name>
      <address>
        <city>Bad Krozingen</city>
        <zip>79189</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vivantes Klinikum Neukölln</name>
      <address>
        <city>Berlin</city>
        <zip>12351</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ev. Krankenhaus Hubertus</name>
      <address>
        <city>Berlin</city>
        <zip>14129</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Otto-von-Guericke-Universität Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <zip>39130</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deutsches Herzzentrum München</name>
      <address>
        <city>München</city>
        <zip>80636</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RoMed Klinikum Rosenheim</name>
      <address>
        <city>Rosenheim</city>
        <zip>83022</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>October 23, 2013</study_first_submitted>
  <study_first_submitted_qc>October 23, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2013</study_first_posted>
  <last_update_submitted>March 27, 2020</last_update_submitted>
  <last_update_submitted_qc>March 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

